WO2008010335A1 - Extrait végétal ayant un effet préventif sur l'arthrite - Google Patents

Extrait végétal ayant un effet préventif sur l'arthrite Download PDF

Info

Publication number
WO2008010335A1
WO2008010335A1 PCT/JP2007/057108 JP2007057108W WO2008010335A1 WO 2008010335 A1 WO2008010335 A1 WO 2008010335A1 JP 2007057108 W JP2007057108 W JP 2007057108W WO 2008010335 A1 WO2008010335 A1 WO 2008010335A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
joint
asteraceae
parthenolide
arthritis
Prior art date
Application number
PCT/JP2007/057108
Other languages
English (en)
Japanese (ja)
Inventor
Tetsuya Tomita
Osamu Masaki
Original Assignee
Mmt Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mmt Co., Ltd. filed Critical Mmt Co., Ltd.
Publication of WO2008010335A1 publication Critical patent/WO2008010335A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to a food and drink containing an Asteraceae plant extract, particularly a feverfew extract, or valthenolide, which is an active ingredient thereof, which has an effect of suppressing joint disease or a disease that is advantageous for suppressing NF ⁇ B. Products, supplements and medicines.
  • methotrexate is widely used for the treatment of arthritis, but there are problems of side effects (especially the elderly), and there are not a few ineffective cases. In addition, there are quite a few patients who cannot suppress the progression of joint destruction with methotrexate alone.
  • Non-Patent Document 1 Merck Manual 16th Edition
  • Non-Patent Document 2 Japanese Medicinal Products Collection January 1997 edition
  • the present inventors have conducted intensive research and found that the above problems can be solved by using an Asteraceae plant extract containing sesquiterpene ratatones, particularly feverfew extract, or parthenolide which is an active ingredient thereof.
  • the present invention has been completed.
  • Asteraceae plants especially Nashirogiku, which is a natural material that is effective for joint diseases or diseases that are advantageous to suppress NF ⁇ , and can be administered orally with few side effects and can be obtained in large quantities and at low cost.
  • Foods and drinks, supplements, and medicines containing baltenolide are provided.
  • FIG. 1 is a graph showing the time course of arthritis scores when feverfew extract or parthenolide is administered to mice.
  • the black circle is the vehicle control group
  • the white square is the parthenolide 50 mg / kg / day administration group
  • the black triangle is the feverfew extract 222 mg / kg / day administration group.
  • Each data is the average soil standard deviation of 10 animals.
  • the data for * is p 0.05 and the data for * is p 0.01.
  • FIG. 2 is a graph showing arthritis scores in the case of administration of parthenolide or feverfew extract on the same day as the onset of arthritis or 4 days after onset in mice.
  • CAIA is the untreated arthritis group
  • vehicle (dO) is the group given methylcellulose on the same day as the onset of joint
  • PTL (dO) is the group given parthenolide on the same day as the onset of joint
  • PT L (d4) is Data for the group that received valtenolide 4 days after the onset of the joint
  • feverfew (d4) for the group that received the feverfew extract 4 days after the onset of the joint.
  • Fig. 3 is a view showing the suppression of expression of NF ⁇ B lower layer gene in ankle joint when parthenolide is administered 4 days after the onset of arthritis in mice.
  • Figure 3a shows IL-1 ⁇
  • Figure 3b shows TNF
  • Figure 3c shows MMP_9
  • Figure 3d shows MIP_1 expression.
  • Fig. 4 shows parthenolide 3 hours after degeneration of normal human chondrocytes It is a figure which shows the expression suppression of the lower layer gene of NF (kappa) sputum when added.
  • Fig. 4a shows IL 1 ⁇
  • Fig. 4b shows ⁇ -1
  • Fig. 4c shows MMP-3
  • Fig. 4d shows TNF ⁇ expression.
  • FIG. 5 is a diagram showing suppression of expression of NF ⁇ NF lower layer genes when feverfew extract is added to synovial cells obtained from rheumatic patients.
  • Fig. 5a shows IL-1 / 3
  • Fig. 5b shows TNF
  • Fig. 5c shows MMP_1
  • Fig. 5d shows MMP-3 expression.
  • the present invention provides the following:
  • the Asteraceae plant is feverfew, (1) Nile, (3) L, food or drink according to any of the above;
  • a pharmaceutical composition for preventing or treating joint diseases comprising an extract of Asteraceae or valthenolide;
  • the present invention relates to the prevention or treatment of joint diseases, comprising an extract of a plant containing sesquiterpene ratatones. It is related to food and drink to do. If the plant extract used in the food or drink of the present invention is a plant extract containing sesquiterpene ratatones, the type of plant is not particularly limited. Examples of plants containing a large amount of sesquiterpene ratatones include asteraceae plants, such as plants of the genus Artemisia and dandelions.
  • the present invention provides a food and drink for preventing or treating joint diseases, which contains an extract of a asteraceae plant.
  • parthenolide is a substance that has been reported to have various physiological activities so far.
  • the arthritis inhibitory effect in the present invention is mainly derived from parthenolide. available. Therefore, it is preferable to use a plant having a high parthenolide content.
  • Such plants include Asteraceae plants, preferably plants belonging to the genus Artemisia, particularly preferably feverfew. (Tanacetum parthenium) (also called Fever-Fu). Therefore, a particularly preferred plant extract used in the present invention is feverfew extract.
  • Feverfew plants especially leaves, usually contain about 0.2-0.9% parthenolide.
  • parthenolide Surprisingly, it has been found that when feverfew extract is orally administered to animals, the same effect as with parthenolide alone can be obtained even if only a very small amount of bartenolide is administered in terms of bartenolide. (See Examples).
  • the plant extract can be obtained by a general method.
  • the extraction site may be any site as long as it is an aerial part of the plant, but in the case of an Asteraceae plant such as feverfew, a preferable extraction site is a leaf.
  • Extracts can be obtained by immersing the plant in a solvent as it is, but extraction efficiency is higher by crushing and extracting the contents.
  • Plants can be raw or dried. For drying, a known drying method such as warm air drying or air drying can be used. Various plant crushing means can be used.
  • Suspension / extraction media include ether, methanol, ethanol, or a mixture of ethanol and water. Suspension media should be less toxic or non-toxic. From the standpoint of strength, ethanol or a mixture of ethanol and water is particularly preferable as a suspension / extraction medium.
  • Extraction conditions such as temperature and time during suspension 'extraction can be selected according to the type and amount of plants. Usually, it is extracted at room temperature and normal pressure for several hours to several days.
  • the above-ground parts of plants for example, leaf candy and the like, are dried by a known drying method such as warm air drying or air drying, and pulverized to obtain a food or drink or pharmaceutical composition of the present invention. May be used for things
  • the obtained extract can be subjected to decantation, filtration, centrifugation, or the like to remove solids and particulate matter.
  • the obtained extract may be concentrated by a known method such as evaporation.
  • the obtained extract is known It may be used after further purification by methods such as various chromatographic and precipitation methods.
  • the plant extract used in the food and drink of the present invention can be obtained as described above, but the nashirogiku extract is also sold and can be used. These extracts can be made into various forms according to usage forms, purposes, etc., and can be prepared into liquids, semi-solids, powders (for example, freeze-dried powders, etc.).
  • An Asteraceae plant extract can be blended with various foods to obtain the foods and drinks of the present invention.
  • These asteraceae plant extracts are of low toxicity or non-toxic because they are derived from natural products, and can be incorporated into any food or drink.
  • the extract may be blended in juices or herbal seasonings.
  • the food and drink of the present invention can be a health food, a functional nutritional food, or a food for specified health use (so-called “tokuho”).
  • supplements are mentioned as a preferred form of the food and drink of the present invention.
  • the supplement may be in any shape that can be taken orally, such as tablets, capsules, granules, and powders (e.g., freeze-dried powder). Etc.), suspensions, drinks, IJs, elixirs, tiable forms, jelly forms, etc.
  • These supplements can be produced according to processes used in the food and pharmaceutical fields. For example, when manufacturing a tablet-shaped supplement, a general process such as mixing, drying, and tableting used in the pharmaceutical field can be used. For example, in the case of a capsule form, a general process such as mixing and encapsulation can be used.
  • Soft capsules and hard capsules can also be appropriately selected according to the purpose.
  • the extract can be dissolved or suspended in a less toxic medium such as ethanol.
  • a less toxic medium such as ethanol.
  • powder and granule supplements it is still possible to use conventional processes such as mixing, drying, grinding and sieving.
  • a carrier or excipient is used in the production of supplements, the type and amount can be selected according to the practice in the pharmaceutical field.
  • solid carriers or excipients include talc, carboxymethylcellulose, sucrose, and wheat flour.
  • the liquid carrier include water, ethanol, and edible fats and oils.
  • arthritis such as infectious arthritis due to viral infection of bacteria, rheumatoid arthritis, arthritis due to gout, psoriatic arthritis, etc. It is effective for the treatment and prevention of osteoarthritis and joint destruction.
  • the food and drink of the present invention particularly those containing feverfew extract, are considered to have a function of controlling NF / c B, feverfew extract, in addition to the above diseases, glomerulonephritis, arteries It is effective in the treatment and prevention of diseases such as sclerosis, atopy and asthma.
  • Asteraceae extract per day depends on the amount of sesquiterpene ratatones contained, particularly parthenolide. In the case of feverfew extract, it is common to take about 0.05g to 50g per day for adults (body weight 70kg), and it is appropriate to take about 0.15g to 15g.
  • the food and drink or supplement of the present invention not only asteraceae plant extracts but also one or more other active ingredients may be mixed.
  • the food and drink of the present invention may be used in combination with other ingredients effective for joint diseases such as dalcosamine, chondroitin, and calcium. It is also possible for a person who has already been treated for a joint disease to promote the therapeutic effect by eating the food or drink of the present invention.
  • feverfew extract is thought to regulate NF / c B and may act by a mechanism different from conventional arthritis therapeutics, so the pharmaceutical composition of the present invention synergizes with these drugs there is a possibility.
  • the present invention provides a pharmaceutical composition for treating a joint disease, comprising an extract of an Asteraceae plant.
  • the active ingredient in the pharmaceutical composition of the present invention is the above-mentioned Asteraceae plant extract, preferably feverfew extract.
  • those obtained by purifying these extracts to increase the parthenolide content may be used.
  • sesquiterpene ratatones, preferably panoretenolide may be used as an active ingredient of the pharmaceutical composition of the present invention.
  • panoretenolide includes parthenolide and analogs and derivatives thereof.
  • the pharmaceutical composition of the present invention can be formulated into various dosage forms.
  • the pharmaceutical composition of the present invention is for example, tablets, capsules, granules, powders, drinks and the like are preferable to have a dosage form suitable for oral administration.
  • sesquiterpene ratatones such as parthenolide are used as the active ingredient
  • the pharmaceutical composition of the present invention is preferably in a dosage form suitable for oral administration and topical administration, but administration by other administration routes. Is also possible.
  • These dosage forms can be produced by methods known in the pharmaceutical field.
  • the pharmaceutical composition of the present invention is effective in the treatment and prevention of all joint diseases, particularly infectious arthritis due to viral or bacterial infection, rheumatoid arthritis, arthritis due to gout, psoriatic arthritis, etc. It is effective in the treatment and prevention of arthritis, osteoarthritis and joint destruction.
  • parthenolide in an Asteraceae plant, especially feverfew extract has an action of controlling NF ⁇ B. Therefore, the pharmaceutical composition of the present invention is beneficial to control NFicB in addition to the above diseases. It is effective in the treatment and prevention of various diseases such as glomerulonephritis, arteriosclerosis, atopy and asthma.
  • the active ingredient in the pharmaceutical composition of the present invention is an Asteraceae plant extract, taking a feverfew extract as an example, the daily dosage is 0 per day for an adult (body weight 70 kg). It is common to take about 05g to 5Og, and it is appropriate to take about 0.15g to 15g. In addition, when using parthenolide (single product without extract), the daily dose (oral administration) is generally 0.45 mg to 450 mg per day for adults (70 kg body weight). 1. 35mg ⁇ : About 135mg is appropriate.
  • the pharmaceutical composition of the present invention not only asteraceae plant extracts and parthenolides but also one or more other active ingredients may be mixed.
  • other components effective for joint diseases such as known anti-inflammatory drugs such as steroids and non-steroids, darcosamine, chondroitin, and calcium may be contained in the pharmaceutical composition of the present invention.
  • a person who has already been treated for arthritis can promote the therapeutic effect by using the pharmaceutical composition of the present invention in combination.
  • Parthenolides in the Asteraceae plants, especially feverfew extract are thought to regulate NF ⁇ B and may act by a mechanism different from conventional arthritis therapeutic agents. There is a possibility of synergistic effects.
  • the present invention provides an extract of Asteraceae plant, preferably feverfew extract.
  • a method for preventing or treating joint diseases such as arthritis, osteoarthritis, and joint destruction characterized by feeding an object to a subject.
  • the present invention also relates to a method for preventing or treating joint diseases such as arthritis, osteoarthritis and joint destruction, characterized by administering to the subject a asteraceae plant extract, preferably feverfew extract or parthenolide. provide.
  • the Asteraceae plant extract may be consumed as food or drink.
  • the asteraceae plant extract or valenolide may be administered as a pharmaceutical composition. You can combine power and treatment with other joint disease treatments.
  • the treatment or prevention method of the present invention May have a synergistic effect with the treatment or prevention methods using these drugs.
  • the present invention is beneficial to control NF ⁇ B, which is characterized by feeding a compositae plant extract, preferably a feverfew extract, to a subject.
  • a method for preventing or treating diseases such as glomerulonephritis, arteriosclerosis, atopy and asthma.
  • the present invention relates to a disease beneficial to control NF ⁇ B, such as glomerulonephritis, arteriosclerosis, atopy, characterized by administration of an Asteraceae plant extract, preferably a feverfew extract, or parthenolide. Also provided are methods for preventing or treating diseases such as asthma.
  • the present invention provides an extract of Asteraceae plant, preferably feverfew extract, for the production of food and drink for preventing or treating joint diseases such as arthritis, osteoarthritis and joint destruction.
  • the present invention relates to an extract of a asteraceae plant extract, preferably feverfew extract, or baltenolide for the manufacture of a pharmaceutical composition for preventing or treating joint diseases such as arthritis, osteoarthritis and joint destruction.
  • other joint disease treatments may be used in combination.
  • Parthenolide and extracts from the family Asteraceae, especially feverfew are considered to regulate NF ⁇ B and may act by a mechanism different from conventional therapeutic agents for joint diseases.
  • the composition may produce a synergistic effect with these drugs.
  • the present invention provides a disease in which it is beneficial to control NF ⁇ B, such as glomerulonephritis, arteriosclerosis, atopy, asthma.
  • a disease in which it is beneficial to control NF ⁇ B such as glomerulonephritis, arteriosclerosis, atopy, asthma.
  • the present invention relates to a chrysanthemum preparation for the production of a pharmaceutical composition for the prevention or treatment of diseases for which NF ⁇ B is beneficially controlled, for example, glomerulonephritis, arteriosclerosis, atopy, asthma and the like.
  • a family plant extract preferably feverfew extract, or valenolide.
  • Feverfew Extract (batch number: 051016-107) manufactured by HANDA FINE CHEMICALS was used as the feverfew extract.
  • the content of parthenolide in this extract was about 0.9%.
  • Parthenolide manufactured by sigma (purity of 90% or more) was used.
  • the feverfew extract and parthenolide were dissolved in 0.5 w / v% aqueous methylcellulose solution and orally administered to the animals using a metal sonde (twice a day, dose volume 10 mL / kg / dose).
  • the doses of feverfew extract were 222 mg / kg / day and 888 mg / kg / day, and the dose of parthenolide was 50 mgZkg / day.
  • the vehicle control group received 0.5 w / v% methylcellulose aqueous solution.
  • the number of animals per experiment was 10.
  • mice Male BALB / Cr Slc (SPF) mice, which were 6 weeks old and weighed 19-24g, and were used for the experiment after acclimatization for 7 days.
  • the inflammation score was scored by observing the joints.
  • the scoring criteria are as follows: 0: Normal joint.
  • Figure 1 shows the experimental results. In both the parthenolide administration group and the feverfew extract administration group, an arthritis inhibitory effect was observed. Indicated. If the parthenolide content in feverfew extract is 0.9%, the dosage of feverfew extract 222 mgZkgZ days corresponds to parthenolide 2. Omg / mg / day. It is surprising that such a high arthritis inhibitory effect was obtained by oral administration. The reason may be a synergistic effect of other components contained in the feverfew extract.
  • the safety of the feverfew extract used in the above experiment was examined.
  • the test method was a fixed dose method based on the E CD Chemical Test Guideline (TG420), and Sic: ICR female mice were used.
  • TG420 E CD Chemical Test Guideline
  • Sic ICR female mice were used.
  • the LD value of pear extract was over 2000 mg / kg.
  • the mutagenicity of the feverfew extract used in the above experiments was determined using Salmonell atyphimurium TA100, TA1535, TA98, TA1537 and Escherichia coli WP2 uvrA as test bacteria in the absence and presence of S9mix. Examined. As a result, mutagenicity was not observed even at a dose of 5000 ⁇ / plate. From these results, it was found that feverfew extract is extremely safe and high.
  • parthenolide (Sigma) was dissolved in a 0.5 w / v% methylcellulose aqueous solution and orally administered to animals using a plastic sonde (1 day). 2 times 25mg / kg / time).
  • feverfew extract extract group feverfew extract (Fever few Extract batch number 609M907-235, manufactured by Handa Fine Chemicals) was dissolved in 0.5 wZv% methylcellulose aqueous solution and orally administered to animals using a plastic sonde. (220mg / kgZ twice a day).
  • the vehicle control group was given a 0.5 wZv% methylcellulose solution.
  • the redness and swelling of the ankle joint were observed after 7 and 14 days.
  • Fig. 2 shows changes in joint scores over time. Compared to the vehicle group, the progression of arthritis was suppressed in the parthenolide administration group and feverfew extract extract administration group. In addition, there was no difference between the administration of parthenolide at the same time as the onset of arthritis (valtenolide d0) and the administration of parthenolide and feverfew extract 4 days after the onset of arthritis (parthenolide d4, feverfew extract d4). It was a result.
  • parthenolide manufactured by sigma was dissolved in an aqueous 0.5 wZv% methylcellulose solution and orally administered to the animals using a plastic sonde. (Twice a day, 25 mgZkg / dose) A 0.5 wZv% methylcellulose solution was given to the vehicle group. After 14 days of slaughter, tota 1 RNA was extracted from the ankle joint, and the effect of suppressing the progression of arthritis was examined at the gene level. Gene expression was examined by real-time PCR (RT_PCR).
  • IL-l j3 was added to cause degeneration.
  • vartenolide manufactured by Sigma
  • N 3
  • the concentration of parthenolide was examined at 20 zg / ml (final concentration) (experiment with 5 ⁇ 10 5 cells per ml).
  • Gene expression was examined by RT-PCR.
  • the present invention is useful in the fields of health foods, functional foods and pharmaceuticals.

Abstract

La présente invention concerne un extrait de plante appartenant à la famille des Compositae, de préférence une plante de Tanacetum parthenium, qui contient une sesquiterpène lactone, ou une boisson/ un aliment, un produit quasi médicamenteux ou une composition quasi pharmaceutique qui contient du parthénolide, en vue de la prévention ou du traitement d'une maladie articulaire ou d'une maladie pour laquelle l'inhibition du facteur NFϰB est efficace. L'invention concerne également un procédé de prévention ou de traitement d'une maladie articulaire ou d'une maladie pour laquelle l'inhibition du facteur NFϰB est efficace, le procédé consistant à faire suivre à un sujet un régime à base d'un extrait de plante appartenant à la famille des Compositae, de préférence une plante de Tanacetum parthenium, qui contient une sesquiterpène lactone, ou à administrer ledit extrait au sujet, ou encore à faire suivre à un sujet un régime à base de parthénolide, ou à administrer du parthénolide au sujet.
PCT/JP2007/057108 2006-07-21 2007-03-30 Extrait végétal ayant un effet préventif sur l'arthrite WO2008010335A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006199643 2006-07-21
JP2006-199643 2006-07-21

Publications (1)

Publication Number Publication Date
WO2008010335A1 true WO2008010335A1 (fr) 2008-01-24

Family

ID=38956670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/057108 WO2008010335A1 (fr) 2006-07-21 2007-03-30 Extrait végétal ayant un effet préventif sur l'arthrite

Country Status (1)

Country Link
WO (1) WO2008010335A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013403A (ja) * 2008-07-04 2010-01-21 Kao Corp Ｎｆａｔシグナル阻害剤及びｎｆａｔシグナル阻害方法
JP2012006838A (ja) * 2010-06-22 2012-01-12 Sansho Seiyaku Co Ltd 皮膚外用剤
WO2013100136A1 (fr) 2011-12-28 2013-07-04 株式会社マルハニチロ食品 Inhibiteur de dégranulation contenant de la chlorophylle c
CN105646515A (zh) * 2015-12-28 2016-06-08 陕西嘉禾生物科技股份有限公司 一种小白菊内酯的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10512573A (ja) * 1995-01-26 1998-12-02 アシュベリー リサーチ コーポレーション セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
WO2004112819A1 (fr) * 2003-06-13 2004-12-29 Gelstat Corporation Compositions et methodes de traitement au moyen d'extraits de plantes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10512573A (ja) * 1995-01-26 1998-12-02 アシュベリー リサーチ コーポレーション セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
WO2004112819A1 (fr) * 2003-06-13 2004-12-29 Gelstat Corporation Compositions et methodes de traitement au moyen d'extraits de plantes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] YIP K.H.M. ET AL.: "Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity", XP003020506, Database accession no. (2005:59604) *
JOURNAL OF BONE AND MINERAL RESEARCH, vol. 19, no. 11, 2004, pages 1905 - 1916 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013403A (ja) * 2008-07-04 2010-01-21 Kao Corp Ｎｆａｔシグナル阻害剤及びｎｆａｔシグナル阻害方法
JP2012006838A (ja) * 2010-06-22 2012-01-12 Sansho Seiyaku Co Ltd 皮膚外用剤
WO2013100136A1 (fr) 2011-12-28 2013-07-04 株式会社マルハニチロ食品 Inhibiteur de dégranulation contenant de la chlorophylle c
US9636326B2 (en) 2011-12-28 2017-05-02 Maruha Nichiro Corporation Chlorophyll c containing degranulation suppressor
US9693996B1 (en) 2011-12-28 2017-07-04 Maruha Nichiro Corporation Chlorophyll c containing degranulation suppressor
CN105646515A (zh) * 2015-12-28 2016-06-08 陕西嘉禾生物科技股份有限公司 一种小白菊内酯的制备方法

Similar Documents

Publication Publication Date Title
JPH0834742A (ja) 多酵素系の使用による生薬の調製、調製された生薬、およびそれらの使用
Siveen et al. Augmentation of humoral and cell mediated immune responses by Thujone
WO2001074352A1 (fr) Compositions somniferes
JP6966998B2 (ja) 口腔、咽喉及び気道の障害の治療のための配合物
CN114502184A (zh) 防治冠状病毒感染的包括杜英萃取物的药物和食品组合物
KR101396458B1 (ko) 천년초 발효물 함유 식품 또는 음료 조성물
EP2347757B1 (fr) Comprimé d allicine naturelle et procédé de préparation de celui-ci
WO2004112773A1 (fr) Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration
WO2008010335A1 (fr) Extrait végétal ayant un effet préventif sur l'arthrite
JPWO2006135084A1 (ja) 脂肪性肝炎または脂肪肝の予防または治療薬
Mirza et al. Shilajit: An ancient panacea
KR20090007281A (ko) 소양증 및 염증을 억제·완화하기 위한 의약 및 기능성 식품
KR101999742B1 (ko) 참취 추출물을 유효성분으로 포함하는 신경병증성 통증 예방 또는 치료용 조성물
KR100809584B1 (ko) 글루코사민과 피니톨을 유효성분으로 하는 염증성 질환의예방 및 치료용 조성물
KR101899555B1 (ko) 노각나무 추출물 및 옻나무 추출물을 함유하는 관절염의 개선, 예방 또는 치료용 조성물
KR101680013B1 (ko) 자단향 추출물을 유효성분으로 함유하는 알레르기성 질환 예방 또는 치료용 약학적 조성물
JP2007031302A (ja) アディポネクチン産生促進剤、及び代謝異常症候群予防剤
JP2007014281A (ja) 噴霧摂取可能な液状食品組成物及びその製造方法
KR101528557B1 (ko) 천년초 발효물 함유 의약 조성물
WO2021240293A1 (fr) Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire
CN101816708B (zh) 治疗风湿病的中药组合物及其制备方法
JP2005015414A (ja) アレルギー性疾患の症状を抑制・緩和するための薬剤または機能性食品
JP2006290794A (ja) 抗ヘリコバクター・ピロリ活性を有する植物発酵物
JP5550995B2 (ja) 尿酸値低下組成物
JP2003286181A (ja) アトピー性皮膚炎易発症体質改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07740544

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 07740544

Country of ref document: EP

Kind code of ref document: A1